Radcliffe Cardiology has announced New Horizons in Dyslipidaemia 2026, a live virtual event on 12 February 2026 (14:00–17:55 GMT) that will convene twelve international leaders to examine how lipid management is evolving, and where current practice continues to fall short.

Despite the availability of highly effective lipid-lowering therapies, residual cardiovascular risk remains common. At the same time, novel agents targeting triglycerides, lipoprotein(a) and LDL-cholesterol, alongside advancing understanding of inflammation and plaque biology, are reshaping prevention strategies. For clinicians, the challenge is no longer awareness, but interpretation, prioritisation and implementation.

This meeting is designed to address that challenge directly.

Scientific Focus

The programme will critically examine emerging data across the lipid spectrum, with emphasis on mechanism-driven decision-making, real-world treatment gaps and alignment with evolving international guidelines.

Participants will:

• Gain expert insight into emerging concepts in lipid biology, including residual risk and inflammatory pathways
• Interpret new clinical evidence across lipid-lowering drug classes
• Review recent guideline updates and assess their implications for daily practice
• Evaluate the future landscape of lipid management, including unmet clinical needs and emerging therapies

Programme Highlights

Triglycerides and Remnant Cholesterol
Once considered secondary targets, triglycerides and remnant particles are now recognised as clinically relevant contributors to cardiovascular risk. This session addresses severe hypertriglyceridaemia, pancreatitis risk, remnant cholesterol and evolving therapeutic strategies.

Chair: Prof Erik Stroes (Amsterdam UMC)

LDL-Cholesterol: Beyond Established Pathways
While PCSK9 inhibition marked a step-change in LDL-cholesterol management, real-world target attainment remains inconsistent. Speakers will examine CETP inhibition, oral PCSK9 inhibitors and CRISPR-based approaches, with a focus on clinical relevance.

Chair: Prof Kausik Ray (Imperial College London)

Lipoprotein(a): From Genetic Marker to Clinical Target
Lp(a) has transitioned from epidemiological interest to actionable risk factor. This session focuses on testing strategies, treatment effects and implications for family-based risk assessment.

Chair: Prof Peter Libby (Harvard Medical School)

Implementation: Translating Evidence into Care
The final session addresses what determines outcomes in practice—patient selection, sequencing of therapies, plaque biology and real-world barriers to implementation.

Chairs: Prof Kausik Ray and Prof Erik Stroes

Unlike traditional conferences focused on isolated lipid parameters or single drug classes, New Horizons in Dyslipidaemia 2026 brings together the architects of contemporary lipid practice in a single, tightly structured programme. The meeting integrates biology, clinical trial evidence, guideline interpretation and real-world implementation—from triglycerides and LDL-cholesterol to lipoprotein(a) and residual risk—within one afternoon.

For clinicians navigating rapidly expanding therapeutic options and evolving recommendations, this format offers a rare opportunity to hear how leading experts are synthesising evidence and applying it in practice, rather than reviewing data in isolation.

Intended Audience

The programme is designed for clinicians directly involved in cardiovascular risk management, including:

• General and interventional cardiologists
• Lipid specialists
• Primary care physicians
• Endocrinologists

Register Now

Your place is waiting: www.newhorizonsindyslipidaemia.com/2026

Questions? Contact Radcliffe Cardiology for media, partnership, or technical enquiries.

Website: www.radcliffecardiology.com

This educational activity is intended for healthcare professionals only.
Programme subject to change. CME accreditation details provided upon registration.